Across TCGA pan-cancer cohorts, KCNMB3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCNMB3 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KCNMB3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCNMB3 expression acts as an unfavorable survival marker.
BLCA, LIHC, and SKCM are the cancer types where KCNMB3 Mutation most reproducibly stratifies survival.